Abstract
Due to inadequate efficacy of antidepressants, various new chemical entities and agents of natural origin have been tested for therapeutic efficacy both alone and to augment existing antidepressants, producing varied clinical results. This article summarizes the basic properties of curcumin and its mechanisms of action, with specific emphasis on the etiopathogenesis of depression, preclinical and current clinical evidence, and future research directions, to better understand the possible role of curcumin in treating depression. Curcumin may have antidepressant activities with diverse mechanisms of action involving primarily neurotransmitters, transcription pathways, neurogenesis, the hypothalamic-pituitary-adrenal axis and inflammatory and immune pathways, as demonstrated in various animal and human studies. Current published randomized clinical trials suggest a small, non-significant benefit of curcumin for major depression. More adequately-powered and methodologically improved studies are mandatory.
Original language | English |
---|---|
Pages (from-to) | 269-280 |
Number of pages | 12 |
Journal | Expert Review of Neurotherapeutics |
Volume | 15 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2015 Mar 1 |
Bibliographical note
Funding Information:This work was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C0003).
Publisher Copyright:
© Informa UK, Ltd.
Keywords
- antidepressant
- curcumin
- depression
- mechanism of action
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology
- Pharmacology (medical)